BiotechTube

Cisplatin liposomal

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteosarcoma Metastatic

Conditions

Osteosarcoma Metastatic

Trial Timeline

Jan 12, 2005 → Mar 17, 2008

NCT ID
NCT00102531

About Cisplatin liposomal

Cisplatin liposomal is a phase 1/2 stage product being developed by Insmed for Osteosarcoma Metastatic. The current trial status is completed. This product is registered under clinical trial identifier NCT00102531. Target conditions include Osteosarcoma Metastatic.

Hype Score Breakdown

Clinical
9
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00102531Phase 1/2Completed

Competing Products

18 competing products in Osteosarcoma Metastatic

See all competitors
ProductCompanyStageHype Score
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
22
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
35
PemetrexedEli LillyPhase 2
35
pemetrexedEli LillyPhase 2
35
Camrelizumab in Combination With Neoadjuvant ChemotherapyJiangsu Hengrui MedicinePhase 2
31
ApatinibJiangsu Hengrui MedicinePhase 2
31
Olaparib + CeralasertibAstraZenecaPhase 2
39
Saracatinib + PlaceboAstraZenecaPhase 2
27
robatumumabMerckPhase 2
27
PembrolizumabMerckPhase 2
27
pazopanibNovartisPhase 2
27
AvelumabPfizerPhase 2
35
Nivolumab + AzacitidineBristol Myers SquibbPhase 1
33
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
35
CabozantinibIpsenPhase 2
36
Sm-EDTMPJazz PharmaceuticalsPhase 2
24
LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).Lantheus HoldingsPhase 1/2
36
REOLYSIN®Oncolytics BiotechPhase 2
25